Skip to main content

Table 5 EORTC QLQ-H&N35 scoring in the morphologically stable head and neck paraganglioma assessed at the onset and end of the assessment

From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Variables

Baseline QLQ

Post-therapy QLQ

P value

Pain

51.8 ± 22.7

26.8 ± 20.8

0.001

Swallowing

31.4 ± 33.3

17.31 ± 16.6

0.786

Senses (taste and smell)

11.1 ± 24.9

10.1 ± 24.3

0.903

Speech

34.5 ± 22.2

30.2 ± 22.2

0.312

Social eating

31.1 ± 33.3

16.6 ± 16.6

0.107

Social contact

29.6 ± 23.7

19.6 ± 19.5

0.175

Sexuality

28.7 ± 25

31.4 ± 16.6

0.705

Teeth

25.9 ± 33.3

16.6 ± 0.1

0.244

Opening mouth

51.2 ± 50

25.6 ± 33.3

0.158

Dry mouth

17.9 ± 17.2

10.25 ± 16

0.251

Sticky saliva

11.1 ± 16

3.7 ± 10.7

0.112

Coughing

38.4 ± 18.4

20.5 ± 21.6

0.002

Felt ill

43.5 ± 33.3

25.6 ± 33.3

0.031

Painkiller

83.3 ± 38.3

18.5 ± 17

< 0.0001

Nutritional supplement

38.4 ± 50.6

5.1 ± 12.1

0.062